This inventor holds 9 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Curevac Ag, Curevac Se, Curevac Manufacturing Gmbh. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
5 out of 97 
2 out of 67 
1 out of 11 Years Active: 2019-2025
Title: Innovations by Michael Sonntag: A Pioneer in Long-Chain RNA Technology
Introduction
Michael Sonntag, an inventive mind located in Tübingen, Germany, has carved a niche for himself in the field of biotechnology, particularly through his significant contributions to long-chain RNA technology. With a remarkable portfolio comprising nine patents, Sonntag's work is paving the way for future advancements in pharmaceuticals and vaccines.
Latest Patents
Among his latest innovations is a patented dry powder composition that includes a storage-stable formulation of long-chain RNA. This groundbreaking invention focuses not only on the creation of a dry powder formulation through methods such as spray-drying and spray-freeze drying but also extends to its applications in pharmaceutical compositions and vaccines. The formulations aim to treat or prevent disorders and diseases, showcasing versatility and potential for impactful medical usage. Additionally, Sonntag’s patent covers kits of parts that incorporate this dry powder composition, further simplifying the implementation of his innovative solutions in various medical contexts.
Career Highlights
Michael Sonntag has significantly impacted the field of biotechnology through his work at prominent companies, namely Curevac AG and Curevac SE. His experience in these organizations has bolstered his understanding and expertise in developing RNA-based technologies that can be pivotal for future medical treatments. His portfolio reflects a commitment to innovation, particularly in a rapidly evolving industry.
Collaborations
Throughout his career, Sonntag has collaborated with notable professionals, including Fabian Johannes Eber and Thorsten Mutzke. These partnerships have undoubtedly enhanced his research and development efforts, bringing together diverse expertise to further advance the biotechnology landscape.
Conclusion
Michael Sonntag stands out as a leading inventor in long-chain RNA technology, with a diverse array of patents that promise to improve therapeutic approaches for various diseases. As he continues his work in the field, Sonntag's contributions are likely to shape the future of pharmaceutical innovations and pave the way for new medical solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile